News

Two of Alexion’s rare-disease drugs get the thumbs up from the EU


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Two of Alexion’s rare-disease drugs get the thumbs up from the EU

 

Date: 02/07/2015

The European Medicines Agency (EMA) is about to approve a couple of rare diseases drugs developed by Alexion. The two enzymes, Strensiq and Kanuma, received  positive feedback from the EMA’s Committee for Medicinal Products for Human Use, which normally leads to the approval of the drug.

The Committee for Medicinal Products for Human Use has recommended the marketing authorization of Alexion’s Strensiq and Kanuma. Strensiq, asfotase alfa, is indicated in patients with pediatric-onset hypophosphatasia to treat the bone deformities of the disease. On the other side, Kanuma, sebelipase alfa, is indicated for lysosomal acid lipase deficiency. Two rare disorders with no therapies approved for their treatment.

For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019